# Bank of America Corp DE

Type: Company (BAC)

Source: GetYourBrief — https://getyourbrief.com/entity/bank-of-america-corp-de
Canonical HTML page: https://getyourbrief.com/entity/bank-of-america-corp-de

## Timeline

- **2026-08-15**: 13F activity reported by financial media — HoldingsChannel and Bbns publish details on Oppenheimer's new position and other institutional moves in Chubb.
- **2026-07-28**: Insider sale by EVP Joseph F. Wayland — Wayland sells 8,502 shares at an average price of $364.54, totaling $3,099,319.08 and reducing direct ownership by 20.12% to 33,749 shares.
- **2026-06**: Q2 2026 13F reporting period ends — Oppenheimer Asset Management builds a new 118,585-share Chubb position during the quarter, valued at approximately $40,407,000.

## Recent coverage (4 stories, network-wide)

### Oppenheimer Takes New $40.4M Stake in Chubb as Institutions Pile In
2026-08-16 01:03:41 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Oppenheimer Asset Management initiated a $40.4M position in Chubb during Q2 2026, joining late-stage buying from Berkshire, State Street, T. Rowe, GQG, and BofA. Institutional ownership now stands at 83.81%, but a $3.1M insider sale by EVP Joseph Wayland adds nuance.
Full story: https://getfinancebrief.com/story/oppenheimer-40m-chubb-stake-institutional-buying

### SGP Hits $17.56 Low: 156% Upside to $45 Analyst Target
2026-08-10 05:23:16 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Spyglass Pharma's stock plunges to a new 52-week low of $17.56 despite a consensus 'Moderate Buy' rating and an average analyst target of $45. For biotech investors, the 156% upside potential must be weighed against a recent earnings miss and a downgrade to sell, raising questions about near-term pipeline catalysts.
Full story: https://getbiobrief.com/story/spyglass-pharma-52-week-low-156-percent-upside-bio

### AstraZeneca Draws $3.8M+ Institutional Share Accumulation Across 6 Major Funds
2026-06-28 07:45:46 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Six major institutional investors have collectively added over 3.8 million AstraZeneca shares across recent quarters, signaling strong professional confidence in the company's diversified healthcare portfolio spanning oncology, cardiovascular, respiratory, and rare disease treatments. The sustained buying pattern highlights institutional conviction in AstraZeneca's ability to deliver innovative therapies that address critical unmet medical needs.
Full story: https://gethealthbrief.com/story/astrazeneca-institutional-accumulation-healthcare-implications

### Paragon Capital’s 288.8% NVIDIA Boost Mirrors $62.2B Institutional Wave
2026-06-28 03:23:06 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A wave of institutional buying in NVIDIA highlights the stock’s allure, with Paragon Capital’s Q1 2026 filing revealing a 288.8% stake increase. The move underscores how deep the conviction runs among hedge funds and sovereign wealth funds.
Full story: https://getfinancebrief.com/story/finance-nvidia-institutional-paragon-288

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.